A costing study of bortezomib shows equivalence of its real-world costs to conventional treatment

Jane F. Thompson, Zoe Teh, Yiyang Chen, Joanne Gardiner, Jana M. Bednarz, Geoffrey N. Thompson, Cindy Lee, Noemi Horvath, Peter Bardy, David Yeung

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e76-e79
JournalBritish Journal of Haematology
Issue number3
Publication statusPublished - 1 May 2020
Externally publishedYes


  • bortezomib
  • cost of illness
  • economics
  • haematologic diseases
  • medical
  • myeloma
  • novel agents
  • real-world

ASJC Scopus subject areas

  • Hematology

Cite this